Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04432857 |
TitleAN0025 and Pembrolizumab Combination in Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2020-06-16 |
Location
Missouri, United States
Texas, United States Utah, United States Virginia, United States France |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
AN0025, Pembrolizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT04426669 |
TitleA Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | Phase
Phase 1
|
Date Added 2020-06-11 |
Location
Minnesota, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Aldesleukin, Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes (TIL) |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04362839 |
TitleRegorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2020-04-27 |
Location
California, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Ipilimumab, Nivolumab, Regorafenib, Opdivo, Stivarga, Yervoy |
Tags
MSS/ MMRp
|
| NCT ID NCT04332653 |
TitleNT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2020-04-03 |
Location
Florida, United States
Michigan, United States Missouri, United States North Carolina, United States Pennsylvania, United States Tennessee, United States Texas, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Completed
|
Drugs
NT-I7, Pembrolizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT04262687 |
TitleChemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate | Phase
Phase 2
|
Date Added 2020-02-10 |
Location
France
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Bevacizumab, capecitabine, oxaliplatin, Pembrolizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT04185883 |
TitleSotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | Phase
Phase 1
|
Date Added 2019-12-04 |
Location
Arizona, United States
California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Maryland, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Australia Austria Belgium Canada Germany Italy Japan Netherlands South Korea Spain Taiwan United Kingdom |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
afatinib, AMG 404, Atezolizumab, carboplatin, pemetrexed, docetaxel, everolimus, FOLFIRI, FOLFOX, MVASI® (bevacizumab-awwb), palbociclib, panitumumab, Pembrolizumab, RMC-4630, Sotorasib, TNO155, Trametinib |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04130854 |
TitleINNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer | Phase
Phase 2
|
Date Added 2019-10-18 |
Location
Arizona, United States
North Carolina, United States Oregon, United States Texas, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days, mFOLFOX and Radiation Therapy 5Gy x 5 days |
Tags
MSS/ MMRp
|
| NCT ID NCT04117087 |
TitlePooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer | Phase
Phase 1
|
Date Added 2019-10-07 |
Location
Maryland, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Ipilimumab, Nivolumab, Opdivo, Yervoy |
Tags
MSS/ MMRp
|
| NCT ID NCT04111458 |
TitleA Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) | Phase
Phase 1
|
Date Added 2019-10-01 |
Location
Massachusetts, United States
North Carolina, United States Tennessee, United States Texas, United States Germany Netherlands |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
BI 1701963, Trametinib |
Tags
MSS/ MMRp
|
| NCT ID NCT04111172 |
TitleA Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | Phase
Phase 2
|
Date Added 2019-10-01 |
Location
Pennsylvania, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
